Related Experiment Video

Updated: Jul 13, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.1K

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2

Wenjing Chen1, Jong-In Park1

  • 1Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA.

International Journal of Molecular Sciences
|October 14, 2023
PubMed

Insights

BRAF mutations are common in cancer. Dual BRAF/MEK inhibition is effective but faces challenges from intrinsic adaptation and acquired resistance, necessitating further research into resistance mechanisms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • BRAF oncogene mutations occur in approximately 50% of cancers.
  • Targeting BRAF and MEK1/2 is a primary strategy for BRAF-mutant tumors.
  • Dual BRAF/MEK inhibition demonstrates significant efficacy across various BRAF-mutant cancers.

Purpose of the Study:

  • To review and update information on the molecular mechanisms of resistance to BRAF and MEK inhibitors.
  • To analyze the specificity of resistance mechanisms in different BRAF-mutant tumors.
  • To address challenges in improving clinical outcomes for BRAF/MEK targeted therapies.

Main Methods:

  • Literature review of studies on BRAF/MEK inhibition and tumor resistance.
  • Analysis of intrinsic and acquired resistance mechanisms.
  • Examination of signaling, metabolic, and regulatory network rewiring.

Main Results:

  • BRAF-mutant tumors can intrinsically adapt to BRAF/MEK inhibitors by bypassing drug effects.
  • Tumors initially responsive to BRAF/MEK inhibitors often develop acquired resistance through genetic or epigenetic alterations.
  • Understanding these resistance mechanisms is crucial for improving therapeutic strategies.

Conclusions:

  • Intrinsic adaptation and acquired resistance are significant hurdles for BRAF/MEK inhibitor therapies.
  • Identifying molecular mechanisms of resistance is key to overcoming therapeutic limitations.
  • Further research is needed to enhance the clinical efficacy of BRAF/MEK targeted treatments.
Keywords:
BRAFMEKdrug resistancetumor

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K
A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K